Future Science Group
Atkins_FutureOncol_Supplement.docx (27.41 kB)

Supplementary Tables – Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

Download (27.41 kB)
posted on 2022-04-20, 09:23 authored by Figshare Future Science GroupFigshare Future Science Group, Michael B Atkins, Cristina Julian, Matthew H Secrest, Janet Lee, Ana M Abajo-Guijarro, Edward McKenna


Sensitivity analysis 1: Statistical adjustment without inverse probability of treatment weighting (IPTW)


Sensitivity analysis 2: Censoring patients in the practice subanalysis who initiate a therapy off-sequence


Sensitivity analysis 3: Restricting to CPI patients receiving ipilimumab + nivolumab


Supplemental Table 1. Comparison of statistical adjustments with and without inverse probability of treatment weighting (IPTW).


Supplemental Table 2. Baseline Characteristics of Patients With Advanced BRAF-Mt Melanoma by 1L Treatment


F Hoffmann-La Roche Ltd. and Genentech, Inc